Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

Author(s): John V. Heymach, M.D., Ph.D.¹; Gerrina Ruiter, M.D., Ph.D.^2,3; Myung-Ju Ahn, M.D.⁴; Nicolas Girard, M.D., Ph.D.^5,6; Egbert F. Smit, M.D., Ph.D.^3,7; David Planchard, M.D., Ph.D.^8,9; Yi-Long Wu, M.D.¹⁰; Byoung Chul Cho, M.D., Ph.D.¹¹; Noboru Yamamoto, M.D., Ph.D.¹²; Joshua K. Sabari, M.D.¹³; Yanqiu Zhao, M.D.¹⁴; Hai-Yan Tu, M.D.¹⁰; Kiyotaka Yoh, M.D.¹⁵; Ernest Nadal, M.D., Ph.D.¹⁶; Behbood Sadrolhefazi, M.D.¹⁷; Maren Rohrbacher, M.D., Ph.D.¹⁸; Ute von Wangenheim, Ph.D.¹⁹; Sabina Eigenbrod-Giese, M.D., Ph.D.¹⁸; Jon Zugazagoitia, M.D., Ph.D.²⁰; for the Beamion LUNG-1 Investigators;

Source: N Engl J Med 2025;392:2321-2333

Dr. Maen Hussein's Thoughts

Another option for HER-2 lung cancer patients. 71% had an objective response with a duration of 14.1 months and progression-free survival (PFS) of 12.4 months. Grade 3 adverse events were observed in 17% of patients. Some patients had been previously treated with HER-2 ADC therapy.

BACKGROUND

Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor that has been shown to have efficacy in persons with advanced or metastatic solid tumors with HER2 alterations in a phase 1 study.

METHODS

We evaluated zongertinib in a multicohort, phase 1a–1b trial involving patients with advanced or metastatic HER2-mutant NSCLC. Here we report the primary analysis of zongertinib in previously treated patients: those with tumors harboring a mutation in the tyrosine kinase domain (cohort 1), those with tumors harboring a mutation in the tyrosine kinase domain previously treated with a HER2-directed antibody–drug conjugate (cohort 5), and those with tumors harboring a non–tyrosine kinase domain mutation (cohort 3). In cohort 1, patients were initially randomly assigned to receive zongertinib at a dose of 120 mg or 240 mg once daily. Patients in cohorts 5 and 3 initially received 240 mg daily. After an interim analysis of data from cohort 1, subsequently recruited patients across all cohorts received zongertinib at a dose of 120 mg. The primary end point was an objective response assessed by blinded independent central review (cohorts 1 and 5) or by investigator review (cohort 3). Secondary end points included the duration of response and progression-free survival.

RESULTS

In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg. At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0.001 against a ≤30% benchmark) had a confirmed objective response; the median duration of response was 14.1 months (95% CI, 6.9 to not evaluable), and the median progression-free survival was 12.4 months (95% CI, 8.2 to not evaluable). Grade 3 or higher drug-related adverse events occurred in 13 patients (17%). In cohort 5 (31 patients), 48% of the patients (95% CI, 32 to 65) had a confirmed objective response. Grade 3 or higher drug-related adverse events occurred in 1 patient (3%). In cohort 3 (20 patients), 30% of the patients (95% CI, 15 to 52) had a confirmed objective response. Grade 3 or higher drug-related adverse events occurred in 5 patients (25%). Across all three cohorts, no cases of drug-related interstitial lung disease occurred.

CONCLUSIONS

Zongertinib showed clinical benefit with mainly low-grade adverse events in patients with previously treated HER2-mutant NSCLC. (Funded by Boehringer Ingelheim; Beamion LUNG-1 ClinicalTrials.gov number, NCT04886804.)

Author Affiliations

¹Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston; ²Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam; ³Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam; ⁴Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; ⁵Institut Curie, Institut du Thorax Curie-Montsouris, Paris; ⁶Paris-Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Versailles, France; ⁷Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, the Netherlands; ⁸Department of Medical Oncology, Institut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif, France; ⁹Faculty of Medicine, Paris-Saclay University, Paris; ¹⁰Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; ¹¹Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; ¹²Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo; ¹³Division of Medical Oncology, Perlmutter Cancer Center, New York University Langone Health, New York; ¹⁴Department of Medical Oncology, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China; ¹⁵Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; ¹⁶Thoracic Tumors Unit, Medical Oncology, Catalan Institute of Oncology, Bellvitge Biomedical Research institute, L’Hospitalet, Barcelona; ¹⁷Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT; ¹⁸Boehringer Ingelheim International, Ingelheim am Rhein, Germany; ¹⁹Boehringer Ingelheim Pharma, Biberach an der Riss, Germany; ²⁰Department of Medical Oncology, 12 de Octubre Hospital, Madrid;

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer

The phase II trial of neoadjuvant PD-1/PD-L1 blockade plus chemotherapy in borderline resectable and unresectable stage III NSCLC showed a significant improvement in event-free survival (EFS) with the combination (24.1 vs 10.6 months) compared to chemotherapy alone, with a hazard ratio (HR) of 0.62. Major pathological response rates were higher with immunotherapy (44.7% vs 22.3%), and no new safety signals were noted. The regimen improved surgical resection rates (68% vs 52%) without increasing perioperative complications. This validates chemoIO in the neoadjuvant setting particularly in whom we wish to pursue resection or avoid chemoradiation. It would be great to see this compared to chemoradiation followed by immunotherapy rather than chemotherapy alone.

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Results showed the median event-free survival (EFS) was 54.8 months with nivolumab plus ipilimumab vs 20.9 months with chemotherapy. Three-year EFS rates were 56% vs 44%. Three-year overall survival (OS) rates were 73% vs 61% pathologic complete response rates were 20.4% vs 4.6%. This was three cycles of nivolumab and one dose of ipilimumab vs chemotherapy.

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Dato showed a confirmed overall response rate (ORR) of 42.7% with a complete response (CR) of 4.3%. The median duration of response was 7.0 months, with a disease control rate of 86.3% and a median overall survival (OS) of 15.6 months. This could be another option for EGFR mutant patients who had multiple lines of therapy.

Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial

Patients were treated with thoracic and extrathoracic radiation to oligometastatic sites and it seems to help with improving survival, something to consider especially with SBRT now. Do our radiation oncologists have additional input?

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)

Improved progression-free survival (PFS), now we have osimertinib and ramucirumab, amivantamab and Lazertinib (PFS 24.8 vs 23 months but NOT head to head).